Goldman Sachs Small Cap Core Equity ETF(GSC.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Goldman Sachs Small Cap Core Equity ETF
GSC.US
News
View More

BUZZ-Stifel hikes defense firm Kratos' PT on strong drone orders; shares rise

Stifel has raised the price target for Kratos Defense & Security Solutionsfrom $112 to $134, maintaining a "buy" rating. This new target represents a 13.7% upside from the stock's last close. The increase is attributed to strong orders for the Valkyrie drone and advancements in hypersonic programs. KTOS shares rose nearly 2% to about $120 in premarket trading. The brokerage noted Northrop Grumman's selection of KTOS's Valkyrie for the USMC program as a sign of confidence in the company's cost-effective and reliable solutions. 15 of 18 brokerages rate KTOS as "buy" or higher, with a median price target of $100.

Reuters·
US
KTOS
+1.49%
Reuters·
US
KTOS
+1.49%

Revolution Medicines Showcases Pipeline Progress and Phase 3 Trials Targeting RAS-Driven Cancers

Revolution Medicines Inc. has updated its clinical pipeline for RAS-addicted cancers, reporting over 2,500 patients treated with RAS(ON) inhibitors. The company is conducting or planning eight Phase 3 trials for drugs including daraxonrasib, zoldonrasib, elironrasib, and RMC-5127, targeting pancreatic, non-small cell lung, and colorectal cancers. Daraxonrasib has shown promising results in monotherapy and in combination therapies. Ongoing trials for non-small cell lung cancer and completed enrollment for pancreatic cancer are noted. The full presentation is available via a provided link.

Reuters·
US
RVMD
+1.06%
Reuters·
US
RVMD
+1.06%

Kratos Defense Expands Birmingham Operations With New 40,000-Square-Foot Facility

Kratos Defense & Security Solutions Inc. is expanding its Birmingham operations with a new 40,000-square-foot facility, increasing its total footprint to approximately 150,000 square feet. This facility will support the company's growing products sector, including advanced technologies for defense and national security markets. The expansion reflects Kratos' commitment to developing innovative and cost-effective solutions.

Reuters·
US
KTOS
+1.49%
Reuters·
US
KTOS
+1.49%

Here's How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years

Revolution Medicines (NASDAQ:RVMD) has outperformed the market by 13.22% annually over the past 5 years, yielding an average annual return of 26.1%. With a market cap of $22.91 billion, a $100 investment in RVMD five years ago would now be worth $307.60, based on the current price of $118.50. This highlights the significant impact of compounded returns on investment growth over time.

benzinga_article·
US
RVMD
+1.06%
benzinga_article·
US
RVMD
+1.06%

BUZZ-Revolution climbs after report of Merck's up to $32 bln buyout talks

Shares of Revolution Medicinesrose 15% to $123.49 in premarket trading following reports of Merck's potential buyout talks valued at up to $32 billion. Analysts project over $10 billion in sales from Revolution's RAS inhibitor portfolio by 2035. This news comes after AbbVie denied being in acquisition talks with Revolution. RVMD shares have increased approximately 34% since a previous report, boosting its market value to around $20.8 billion. RVMD is currently trading at -16.7 times forward earnings, compared to a five-year average of -9.8.

Reuters·
US
RVMD
+1.06%
Reuters·
US
RVMD
+1.06%
© 2026 Longbridge｜Disclaimer